Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

  • Technology appraisal guidance
  • TA259
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

  1. The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence, University of Warwick:

    • Connock M, Cummins E, Shyangdan D et al. Abiraterone acetate for the treatment of metastatic, castrate‑resistant prostate cancer following previous cytotoxic chemotherapy, December 2011

  2. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

  3. Manufacturer/sponsor:

    • Janssen

  4. Professional/specialist and patient/carer groups:

    • British Association of Urological Surgeons

    • British Uro‑Oncology Group

    • Cancer Research UK

    • Macmillan Cancer Support

    • PCaSO – Prostate Cancer Network

    • Prostate Cancer Charity

    • Prostate Cancer Support Federation

    • Royal College of General Practitioners

    • Royal College of Nursing

    • Royal College of Physicians

    • United Kingdom Clinical Pharmacy Association

    • United Kingdom Oncology Nursing Society

  5. Other consultees:

    • Department of Health

    • NHS Hertfordshire

    • NHS Bradford and Airedale

    • Welsh Government

  6. Commentator organisations (did not provide written evidence and without the right of appeal):

    • British National Formulary

    • Commissioning Support Appraisals Service

    • Department of Health, Social Services and Public Safety for Northern Ireland

    • Healthcare Improvement Scotland

    • MRC Clinical Trials Unit

    • Prostate Action

  7. The following individuals were selected from clinical specialist and patient expert nominations from the non‑manufacturer/sponsor consultees and commentators. They gave their expert personal view on abiraterone by attending the initial Committee discussion and providing written evidence to the Committee. They were invited to comment on the ACD.

    • Dr John Staffurth, , nominated by the RCP on behalf of the NCRI/RCP/RCR/ACP/JCCO and the British Uro‑Oncology Group – clinical specialist

    • Dr Isabel Syndikus clinical expert, nominated by the RCP on behalf of the NCRI/RCP/RCR/ACP/JCCO – clinical specialist

    • Mr Hugh Gunn, nominated by the Prostate Cancer Federation – patient expert

    • Mr Stuart Watson, nominated by the Prostate Cancer Charity – patient expert

  8. The following individuals were nominated as NHS Commissioning experts by the selected NHS trust allocated to this appraisal. They gave their expert/NHS commissioning personal view on abiraterone by attending the initial Committee discussion and providing written evidence to the Committee. They were invited to comment on the ACD.

    • Mrs Rasila Shah, nominated by NHS Hertfordshire – NHS Commissioning expert

  9. Representatives from the following manufacturer/sponsor attended both Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

    • Janssen

Copyright
© National Institute for Health and Clinical Excellence 2012. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not‑for‑profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

ISBN: 978‑1‑4731‑2003‑7